-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
Hepatitis -X- _ O
C -X- _ O
virus -X- _ O
( -X- _ O
HCV -X- _ O
) -X- _ O
is -X- _ O
major -X- _ O
cause -X- _ O
of -X- _ O
liver -X- _ O
cirrhosis -X- _ O
in -X- _ O
humans. -X- _ O
HCV -X- _ O
capsid -X- _ O
( -X- _ O
core -X- _ O
) -X- _ O
protein -X- _ O
( -X- _ O
HCVcp -X- _ O
) -X- _ O
is -X- _ O
a -X- _ O
highly -X- _ O
demanded -X- _ O
antigen -X- _ O
for -X- _ O
various -X- _ O
diagnostic -X- _ O
, -X- _ O
immunization -X- _ O
and -X- _ O
pathogenesis -X- _ O
studies. -X- _ O
Plants -X- _ O
are -X- _ O
considered -X- _ O
as -X- _ O
an -X- _ O
expression -X- _ O
system -X- _ O
for -X- _ O
producing -X- _ O
safe -X- _ O
and -X- _ O
inexpensive -X- _ O
biopharmaceutical -X- _ O
proteins. -X- _ O
Although -X- _ O
invention -X- _ O
of -X- _ O
transgenic -X- _ O
( -X- _ O
stable -X- _ O
) -X- _ O
tobacco -X- _ O
plants -X- _ O
expressing -X- _ O
HCVcp -X- _ O
with -X- _ O
proper -X- _ O
antigenic -X- _ O
properties -X- _ O
was -X- _ O
recently -X- _ O
reported -X- _ O
, -X- _ O
no -X- _ O
data -X- _ O
for -X- _ O
“transient- -X- _ O
expression” -X- _ O
that -X- _ O
is -X- _ O
currently -X- _ O
the -X- _ O
method -X- _ O
of -X- _ O
choice -X- _ O
for -X- _ O
rapid -X- _ O
, -X- _ O
simple -X- _ O
and -X- _ O
lower-priced -X- _ O
protein -X- _ O
expression -X- _ O
in -X- _ O
plants -X- _ O
is -X- _ O
available -X- _ O
for -X- _ O
HCVcp. -X- _ O
OBJECTIVES -X- _ O
: -X- _ O
The -X- _ O
purpose -X- _ O
of -X- _ O
this -X- _ O
study -X- _ O
was -X- _ O
to -X- _ O
design -X- _ O
a -X- _ O
highly -X- _ B-Intervention
codon-optimized -X- _ I-Intervention
HCVcp -X- _ I-Intervention
gene -X- _ O
for -X- _ O
construction -X- _ O
of -X- _ O
an -X- _ O
efficient -X- _ O
transient-plant -X- _ O
expression -X- _ O
system -X- _ O
for -X- _ O
production -X- _ O
of -X- _ O
HCVcp -X- _ O
with -X- _ O
proper -X- _ O
antigenic -X- _ O
properties -X- _ O
in -X- _ O
a -X- _ O
regional -X- _ O
tobacco -X- _ O
plant -X- _ O
( -X- _ O
Iranian -X- _ O
Jafarabadi-cultivar -X- _ O
) -X- _ O
by -X- _ O
evaluation -X- _ O
of -X- _ O
different -X- _ O
classes -X- _ O
of -X- _ O
vectors -X- _ O
and -X- _ O
suppression -X- _ O
of -X- _ O
gene-silencing -X- _ O
in -X- _ O
tobacco. -X- _ O
MATERIALS -X- _ O
AND -X- _ O
METHODS -X- _ O
: -X- _ O
A -X- _ O
codon-optimized -X- _ O
gene -X- _ O
encoding -X- _ O
the -X- _ O
Kozak -X- _ O
sequence -X- _ O
, -X- _ O
6xHis-tag -X- _ O
, -X- _ O
HCVcp -X- _ O
( -X- _ O
1-122 -X- _ O
) -X- _ O
and -X- _ O
KDEL -X- _ O
peptide -X- _ O
in -X- _ O
tandem -X- _ O
( -X- _ O
from -X- _ O
N- -X- _ O
to -X- _ O
C-terminal -X- _ O
) -X- _ O
was -X- _ O
designed -X- _ O
and -X- _ O
inserted -X- _ O
into -X- _ O
potato -X- _ O
virus-X -X- _ O
( -X- _ O
PVX -X- _ O
) -X- _ O
and -X- _ O
classic -X- _ O
pBI121 -X- _ O
binary -X- _ O
vectors -X- _ O
in -X- _ O
separate -X- _ O
cloning -X- _ O
reactions. -X- _ O
The -X- _ O
resulted -X- _ O
recombinant -X- _ O
plasmids -X- _ O
were -X- _ O
transferred -X- _ O
into -X- _ O
Agrobacterium -X- _ O
tumefaciens -X- _ O
and -X- _ O
vacuum -X- _ O
infiltrated -X- _ O
into -X- _ O
tobacco -X- _ B-Patient
leaves. -X- _ I-Patient
The -X- _ O
effect -X- _ O
of -X- _ O
gene -X- _ O
silencing -X- _ O
suppressor -X- _ O
P19 -X- _ O
protein -X- _ O
derived -X- _ O
from -X- _ O
tomato -X- _ O
bushy -X- _ O
stunt -X- _ O
virus -X- _ O
on -X- _ O
the -X- _ O
expression -X- _ B-Intervention
yield -X- _ I-Intervention
of -X- _ I-Intervention
HCVcp -X- _ I-Intervention
by -X- _ O
each -X- _ O
construct -X- _ O
was -X- _ O
also -X- _ O
evaluated -X- _ O
by -X- _ O
co-infiltration -X- _ O
in -X- _ O
separate -X- _ O
groups. -X- _ O
The -X- _ O
expressed -X- _ B-Intervention
HCVcp -X- _ I-Intervention
was -X- _ O
evaluated -X- _ O
by -X- _ O
dot -X- _ O
and -X- _ O
western -X- _ O
blotting -X- _ O
and -X- _ O
ELISA -X- _ O
assays. -X- _ O
RESULTS -X- _ O
: -X- _ O
The -X- _ B-Outcome
codon-optimized -X- _ I-Outcome
gene -X- _ I-Outcome
had -X- _ I-Outcome
an -X- _ I-Outcome
increased -X- _ I-Outcome
adaptation -X- _ I-Outcome
index -X- _ I-Outcome
value -X- _ I-Outcome
( -X- _ I-Outcome
from -X- _ I-Outcome
0.65 -X- _ I-Outcome
to -X- _ I-Outcome
0.85 -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
reduced -X- _ I-Outcome
GC -X- _ I-Outcome
content -X- _ I-Outcome
( -X- _ I-Outcome
from -X- _ I-Outcome
62.62 -X- _ I-Outcome
to -X- _ I-Outcome
51.05 -X- _ I-Outcome
) -X- _ I-Outcome
in -X- _ I-Outcome
tobacco -X- _ I-Outcome
and -X- _ I-Outcome
removed -X- _ I-Outcome
the -X- _ I-Outcome
possible -X- _ I-Outcome
deleterious -X- _ I-Outcome
effect -X- _ I-Outcome
of -X- _ I-Outcome
“GGTAAG” -X- _ I-Outcome
splice -X- _ I-Outcome
site -X- _ I-Outcome
in -X- _ I-Outcome
native -X- _ I-Outcome
HCVcp. -X- _ I-Outcome
Blotting -X- _ I-Outcome
assays -X- _ I-Outcome
via -X- _ I-Outcome
specific -X- _ I-Outcome
antibodies -X- _ I-Outcome
confirmed -X- _ I-Outcome
the -X- _ I-Outcome
expression -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
15 -X- _ I-Outcome
kDa -X- _ I-Outcome
HCVcp. -X- _ I-Outcome
The -X- _ I-Outcome
expression -X- _ I-Outcome
level -X- _ I-Outcome
of -X- _ I-Outcome
HCVcp -X- _ I-Outcome
was -X- _ I-Outcome
enhanced -X- _ I-Outcome
by -X- _ I-Outcome
4-5 -X- _ I-Outcome
times -X- _ I-Outcome
in -X- _ I-Outcome
P19 -X- _ I-Outcome
co-agroinfiltrated -X- _ I-Outcome
plants -X- _ I-Outcome
with -X- _ I-Outcome
better -X- _ I-Outcome
outcomes -X- _ I-Outcome
for -X- _ I-Outcome
PVX -X- _ I-Outcome
, -X- _ I-Outcome
compared -X- _ I-Outcome
to -X- _ I-Outcome
pBI121 -X- _ I-Outcome
vector -X- _ I-Outcome
( -X- _ I-Outcome
0.022 -X- _ I-Outcome
% -X- _ I-Outcome
versus -X- _ I-Outcome
0.019 -X- _ I-Outcome
% -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
total -X- _ I-Outcome
soluble -X- _ I-Outcome
protein -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
The -X- _ I-Outcome
plant-derived -X- _ I-Outcome
HCVcp -X- _ I-Outcome
( -X- _ I-Outcome
pHCVcp -X- _ I-Outcome
) -X- _ I-Outcome
could -X- _ I-Outcome
properly -X- _ I-Outcome
identify -X- _ I-Outcome
the -X- _ I-Outcome
HCVcp -X- _ I-Outcome
antibody -X- _ I-Outcome
in -X- _ I-Outcome
HCV-infected -X- _ I-Outcome
human -X- _ I-Outcome
sera -X- _ I-Outcome
compared -X- _ I-Outcome
to -X- _ I-Outcome
Escherichia -X- _ I-Outcome
coli-derived -X- _ I-Outcome
HCVcp -X- _ I-Outcome
( -X- _ I-Outcome
eHCVcp -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
indicating -X- _ I-Outcome
its -X- _ I-Outcome
potential -X- _ I-Outcome
for -X- _ I-Outcome
diagnostic -X- _ I-Outcome
/ -X- _ I-Outcome
immunization -X- _ I-Outcome
applications. -X- _ I-Outcome
CONCLUSIONS -X- _ O
: -X- _ O
By -X- _ O
employment -X- _ O
of -X- _ O
gene -X- _ O
optimization -X- _ O
strategies -X- _ O
, -X- _ O
use -X- _ B-Outcome
of -X- _ I-Outcome
viral-based -X- _ I-Outcome
vectors -X- _ I-Outcome
and -X- _ I-Outcome
suppression -X- _ I-Outcome
of -X- _ I-Outcome
plant-derived -X- _ I-Outcome
gene -X- _ I-Outcome
silencing -X- _ I-Outcome
effect -X- _ I-Outcome
, -X- _ I-Outcome
efficient -X- _ I-Outcome
transient -X- _ I-Outcome
expression -X- _ I-Outcome
of -X- _ I-Outcome
HCVcp -X- _ I-Outcome
in -X- _ I-Outcome
tobacco -X- _ I-Outcome
with -X- _ I-Outcome
proper -X- _ I-Outcome
antigenic -X- _ I-Outcome
properties -X- _ I-Outcome
could -X- _ I-Outcome
be -X- _ I-Outcome
possible -X- _ I-Outcome
. -X- _ O

